Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2008 Jun 4;25(8):1948–1955. doi: 10.1007/s11095-008-9629-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2008

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Fig. 4 — The influence of Lip-CLOD pretreatment on the effect of Doxil and LCL-PLP on production of pro-angiogenic factors in tumors. Results are presented as % average reduction of the level of tumor pro-angiogenic factors compared to the level of pro-angiogenic factors in control tumors. Control tumors are defined as tumors from mice not treated with Lip-CLOD but treated with PBS. Mean ± SD; n = 17 pro-angiogenic factor levels determined in duplicate per experimental group, Lip-CLOD = treatment only with Lip-CLOD, Lip-CLOD + Doxil = pretreatment with Lip-CLOD followed by Doxil treatment, Lip-CLOD + LCL-PLP = pretreatment with Lip-CLOD followed by LCL-PLP treatment. One-way ANOVA with Dunnett’s Multiple Comparison Test was used; ns not significant (P > 0.05), and** P < 0.01.